China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB 100 million (USD 14.93 million) in a Series B++ financing round. The round was led by SDIC Venture Capital, Guangzhou Development District Investment Group, and Guangzhou Helichuangxing Group Co., Ltd. The proceeds will be used for the clinical development of new product pipelines. Over the past 18 months, the company has accumulated a total of RMB 300 million (USD 44.8 million) through Series B financing.
Product Pipeline
Zhiyi Bio’s lead product SK08, which is expected to complete a Phase II study for diarrhea-predominant irritable bowel syndrome (IBS-D) by the end of this year, has already initiated a Phase Ib / II clinical study in advanced solid tumors in combination with PD-1 inhibitors.-Fineline Info & Tech
